Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Duloxetine 60 mg vs. Cymbalta in Healthy Males
NCT03729284Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of duloxetine in major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic polyneuropathy (DPN), fibromyalgia (FM), chronic musculoskeletal pain, sponsored by Pfizer. Planned start Mar 2020; status: withdrawn.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)diabetic polyneuropathy (DPN)fibromyalgia (FM)chronic musculoskeletal pain
Beyond the preview
Go deeper on NCT03729284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729284.